HSBC keeps HKD 15.45 target for China Medical System stock
Published on 10/17/2026 at 21:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and earnings
- HSBC kept its HKD 15.45 target on September 29, 2026.
- Revenue reached CNY 4.50 billion in the first half of 2026.
- China Medical System stock stood at HKD 10.20 on October 16, 2026, down 2.21 percent versus its HKD 10.43 prior close.
- The trailing dividend yield was 3.37 percent on October 16, 2026.
China Medical System Holdings stock (KYG211081248) closed at HKD 10.20 on October 16, 2026, down 2.21 percent from its HKD 10.43 prior close. Investing.com lists HSBC's HKD 15.45 target dated September 29, 2026, implying 51.47 percent upside to the closing price.
First-half revenue sets the scale
Investing.com reports CNY 4.50 billion of revenue for the first half of 2026, alongside earnings per share of CNY 0.41. The figures were published on August 17, 2026, and provide the latest reported operating marker in this review.
Stock stays above its yearly low
The HKEX close was HKD 7.26 percent above the 52-week low of HKD 9.51 and 34.28 percent below the 52-week high of HKD 15.52 on October 16, 2026. The stock's one-month performance was minus 7.69 percent, while its year-to-date performance was minus 20.99 percent. Trading volume reached 4,697,500 shares against an average volume of 5,455,387 shares.
Valuation and shareholder return
China Medical System had a market capitalization of HKD 24.8 billion, a trailing price earnings ratio of 13.99 and a trailing dividend yield of 3.37 percent on October 16, 2026. The HSBC target of HKD 15.45 stood 51.47 percent above the HKD 10.20 closing price. The company develops, markets and distributes pharmaceutical products in China, with healthcare and specialty drug manufacturing as its principal classifications.
Comparison with peers
China Medical System: minus 2.21 percent, P/E 13.99, market capitalization HKD 24.8 billion
CSPC Pharmaceutical Group (HKEX, HKD): plus 0.17 percent, P/E 11.62, market capitalization HKD 101.3 billion
Sino Biopharmaceutical (HKEX, HKD): minus 0.38 percent, P/E 33.78, market capitalization HKD 93.5 billion
Price and trading position
The October 16 decline left China Medical System below its 52-week midpoint while its valuation remained lower than Sino Biopharmaceutical's price earnings ratio. Its market capitalization was also less than one quarter of CSPC Pharmaceutical Group's, giving the relative scale of the listed peer set.
The further course of trading is shown by the continuously updated real-time quote of China Medical System stock.
China Medical System Holdings market data
- Company: China Medical System Holdings Limited
- ISIN: KYG211081248
- Ticker: 0867
- Primary exchange: HKEX
- Primary-exchange price (as of October 16, 2026, 4:08 p.m. HKT): HKD 10.20
- Change versus prior close: minus 2.21 percent
- Prior close: HKD 10.43
- Market capitalization: HKD 24.8 billion (as of October 16, 2026)
- 52-week range: HKD 9.51-15.52 (as of October 16, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty and Generic
Market context: Current market reports.
